Comparison · NCT03822377-aeacb6fd
Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: Number of Participants With Clinically Relevant Bleeding Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: Number of Participants With Clinically Relevant Bleeding Events. Trial comparisons, record NCT03822377-aeacb6fd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03822377-aeacb6fd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0558 | wilson | |
| Risk in group 2 | 0.0615 | 0.0242 | 0.148 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0615 | -0.148 | 0.00561 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Ticagrelor Orodispersible Tablets than on Ticagrelor Standard Tablets | 16.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ticagrelor Orodispersible Tablets | STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets.~Ticagrelor orodispersible tablets: Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva. | 0 | 65 | OG000 |
| Group 2 | Ticagrelor Standard Tablets | STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills.~Ticagrelor pills: Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water. | 4 | 65 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Clinically Relevant Bleeding Events
- Description
Actionable bleeding events across the two different regimens of Ticagrelor administration, requiring diagnostic studies, hospitalization, or treatment by a health care professional (BARC type 2 or higher)
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
- NCT number
- NCT03822377
- Phases
- PHASE3
- Conditions
- ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
- Interventions
- Ticagrelor orodispersible tablets, Ticagrelor standard tablets
- Lead sponsor
- Azienda Ospedaliero Universitaria di Sassari
- Results first posted
- 2021-09-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03822377?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03822377-aeacb6fd